A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression is a phase 3 interventional study registered as NCT07546500, led by K-, Beta with European Network of Gynaecological Oncological Trial Groups (ENGOT) and GOG Foundation, and recruiting on the registry. Official title: A Randomised, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression. Planned enrolment is 420 participants (estimated). The study started in 2026-04-17 and primary completion is expected in 2028-05-31. No results have been posted on ClinicalTrials.gov.